Table 1. Patient characteristics.
| Variables | GDPH (n=304) | TCGA (n=453) | P | |||
|---|---|---|---|---|---|---|
| No. | (%) | No. | (%) | |||
| Age [median, range] | 48 | [24–82] | 58 | [28–90] | <0.001# | |
| ≤50 years | 169 | 55.6 | 132 | 29.1 | ||
| >50 years | 135 | 44.4 | 321 | 70.9 | ||
| Sex | 0.153 | |||||
| Female | 304 | 100.0 | 449 | 99.1 | ||
| Male | 0 | 0.0 | 4 | 0.9 | ||
| Menopausal Status | <0.001# | |||||
| Pre-menopause | 176 | 57.9 | 120 | 26.5 | ||
| Post-menopause | 128 | 42.1 | 299 | 66.0 | ||
| Missing | 0 | 0.0 | 34 | 7.5 | ||
| LN status | 0.044# | |||||
| Positive | 137 | 45.1 | 229 | 50.6 | ||
| Negative | 167 | 54.9 | 219 | 48.3 | ||
| Missing | 0 | 0.0 | 5 | 1.1 | ||
| TNM stage | 0.162 | |||||
| I–II | 225 | 74.0 | 339 | 74.8 | ||
| III–IV | 79 | 26.0 | 109 | 24.1 | ||
| Missing | 0 | 0.0 | 5 | 1.1 | ||
| Pathological type | <0.001# | |||||
| IDC | 260 | 85.5 | 318 | 70.2 | ||
| ILC | 9 | 3.0 | 85 | 18.8 | ||
| Others | 35 | 11.5 | 50 | 11.0 | ||
| ER status | 0.855 | |||||
| Positive | 240 | 78.9 | 361 | 79.7 | ||
| Negative | 64 | 21.1 | 92 | 20.3 | ||
| PR status | 0.397 | |||||
| Positive | 222 | 73.0 | 310 | 68.4 | ||
| Negative | 81 | 26.6 | 141 | 31.1 | ||
| Missing | 1 | 0.3 | 2 | 0.4 | ||
| HER2 status | 0.054 | |||||
| Positive | 83 | 27.3 | 95 | 21.0 | ||
| Negative | 221 | 72.7 | 358 | 79.0 | ||
| Histologic grade | NA | |||||
| G1 | 17 | 5.6 | – | – | ||
| G2 | 116 | 38.2 | – | – | ||
| G3 | 114 | 37.5 | – | – | ||
| Missing | 7 | 2.3 | 453 | 100.0 | ||
Based on the Pearson χ2 test, the P value is calculated using Fisher’s exact test; #, P value<0.05. LN, lymph node; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.